Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00295178 · ClinicalTrials.gov registry record · Phase 4
Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas
A Phase 4 study of Cellulitis, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT00295178 is a Phase 4 study of Cellulitis that has completed, run by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 80 participants, below the 563-participant average among 11 other Cellulitis trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00295178, a Phase 4 study of Cellulitis, has completed, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to investigate the difference in speed and degree of symptom resolution between daptomycin and vancomycin in subjects treated for cellulitis or erysipelas by evaluation of the following parameters: * Time to erythema margin cessation to progress * Time to defervescence * Time to hospital discharge following relief of the presenting cellulitis or erysipelas * Degree of improvement of the following signs and symptom of cellulitis or erysipelas including * Degree of improvement of cellulitis-related pain and swelling as reported by subjects Additionally, the difference in frequency of Adverse Events between daptomycin and vancomycin will be described.
Conditions Studied
Interventions
- DRUG Vancomycin
- DRUG Daptomycin
Study Locations (1)
Georgia
- Joseph Still Research Foundation - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2006-02-20 |
| Est. Completion | 2006-08-09 |
| Phase | Phase 4 |
Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)42 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00295178
The ClinicalTrials.gov registry entry for NCT00295178 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 563-participant average among 11 other Cellulitis trials with a reported enrollment target (86% lower). The listed sponsor is Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 42 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cellulitis appearing as the primary indexed condition, and to 2 interventions - of which Vancomycin is the first listed.
NCT00295178 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT00295178 about?
NCT00295178 is a clinical study titled "Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas". This study is designed to investigate the difference in speed and degree of symptom resolution between daptomycin and vancomycin in subjects treated for cellulitis or erysipelas by evaluation of the following parameters: * Time to erythema margin cessation to progress * Time to defervescence * Time...
What is the current status of trial NCT00295178?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2006-02-20. Estimated completion is 2006-08-09.
What conditions does trial NCT00295178 study?
This clinical trial studies the following conditions: Cellulitis.
What interventions are being tested in trial NCT00295178?
The interventions under investigation include: Vancomycin (DRUG), Daptomycin (DRUG).
Who is sponsoring clinical trial NCT00295178?
This trial is sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00295178 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cellulitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections
COMPLETED · Phase 4
-
Quasi-Randomized Evaluation of the UCLA Next Day Clinic (NDC)
ACTIVE NOT RECRUITING · NA
-
Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage
COMPLETED · Phase 2
-
Utility of Thermal Imaging in Diagnosis of Cellulitis for Lower Extremity Complaints in the Emergency Department
COMPLETED
-
Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care
COMPLETED · NA
-
Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.